Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature.

Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM.

Methods: This is a cross sectional data from a prospective observational cohort study that evaluated subjects older than 65 y/o with T2D on insulin therapy, with or without oral agents, and HbA1c between 7% and 9%, identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR <30 ml/min; Hb <11g/dL; ALT> 3x ULN; glucocorticoid use in the previous 3 months, and active malignancy were excluded. The diagnosis of sarcopenia was based on the European Working Group on Sarcopenia in Older People (EWGSOP2) . The SARC-F questionnaire was applied and considered high risk if score > 4. Muscle strength was assessed by handgrip strength (HS) using a manual dynamometer (Jamar®) . The muscle mass was assessed by electrical bioimpedance (BIA - Inbody®) obtaining the skeletal muscle mass index (SMI = MM appendicular / height2) . The physical performance was assessed by the timed up-and-go test (TUG) . The presence of sarcopenia was considered when HS <16Kg for women and <27Kg for men and confirmed when SMI <7.00 kg /m2 for men and ≤5.50 kg / m2 for women. The severity was evaluated when TUG was ≥20s.

Results: We assessed 125 patients aged 72.8 ± 5.8 y/o, 53% women and T2D median duration of 21 years (min 1; max 47) ; HbA1c=8.5 ± 1,5%. 50,5% of patients had macrovascular complications history; 25.8% retinopathy; 48,3% neuropathy and 14,3% nephropathy. 18,8% had SARC-F score > 4 indicating high risk of sarcopenia. However, the clinical tests confirmed sarcopenia in only 1,6% of the participants.

Conclusions: The prevalence of sarcopenia in older adults with T2D on insulin treatment was lower than general population, which may be explained by the insulin anabolic effects.


S.A.O.Leite: None. M.Bastos: None. M.Silva: None. A.C.R.Lavalle: None. M.C.Bertogy: None. S.C.Vieira: None. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk.


Abbott Diabetes Care ADC-OUS-IIS-19-47

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at